AI药物研发公司Genesis Therapeutics近日宣布，再次获得英伟达（Nvidia）旗下风险投资部门NVentures的追加投资，具体金额未披露。此举标志着双方合作的进一步深化，旨在加速Genesis的AI平台GEMS(Genesis Exploration of Molecular Space)的开发，该平台专注于利用物理AI进行结构驱动的药物设计。源于斯坦福，深耕分子AIGenesis Therapeutics由Vijay Pande博士在斯坦福大学的实验室衍生而来。联合创始人Evan Feinberg博士在研究生期间与Pande共同发明并撰写了多篇关于深度学习技术的关键论文，其中最引人注目的是Potential
["Hugging Face 获得 2.35 亿美元融资，估值 45 亿美元","Genesis Therapeutics 获得 2 亿美元融资，致力于人工智能药物设计","AI21 Labs 完成 1.55 亿美元 C 轮融资，估值 14 亿美元","Anthropic 获得 1 亿美元融资，与 SKT 合作构建定制大模型","Modular 获得 1 亿美元融资，致力于提供 AI 基础设施"]
["加利福尼亚初创公司 Genesis Therapeutics 成功筹集 2 亿美元资金。","此轮融资由 Andreessen Horowitz 和一家未透露身份的生命科学投资者共同领投。","Genesis 计划利用资金推进其 AI 药物项目的临床试验，并扩大其在新领域的研究。"]
%20--%3e%3cdefs%3e%3cstyle%3e%20.st0%20{%20fill:%20%23061b40;%20}%20.st1%20{%20fill:%20%23306af1;%20}%20.st2%20{%20fill:%20%235ce5cf;%20}%20%3c/style%3e%3c/defs%3e%3cg%3e%3cpath%20class='st0'%20d='M55,10.5h9v3h-9v9h12V7.5h-12v3ZM64,19.5h-6v-3h6v3Z'/%3e%3cpolygon%20class='st0'%20points='69%2016.5%2078%2016.5%2078%2019.5%2069%2019.5%2069%2022.5%2081%2022.5%2081%2013.5%2072%2013.5%2072%2010.5%2081%2010.5%2081%207.5%2069%207.5%2069%2016.5'/%3e%3cpolygon%20class='st0'%20points='95%2010.5%2095%207.5%2083%207.5%2083%2022.5%2095%2022.5%2095%2019.5%2086%2019.5%2086%2016.5%2095%2016.5%2095%2013.5%2086%2013.5%2086%2010.5%2095%2010.5'/%3e%3cpath%20class='st0'%20d='M40,1.5v21h11.6l1.4-1.4v-7.6h0c0,0-1.4-1.5-1.4-1.5l1.4-1.4V2.9l-1.4-1.4h-11.6ZM50,19.5h-7v-6h7v6ZM50,10.5h-7v-6h7v6Z'/%3e%3c/g%3e%3cpath%20class='st1'%20d='M23.1,24L14.7,4.8l-4.9,11.2h3.8l-1.8,4H3.3L12.1,0H2C.9,0,0,.9,0,2v20c0,1.1.9,2,2,2h21.1Z'/%3e%3cpath%20class='st2'%20d='M34,0h-16.8l10.6,24h6.2c1.1,0,2-.9,2-2V2C36,.9,35.1,0,34,0ZM32.5,20h-4V4h4v16Z'/%3e%3c/svg%3e)
